Browsing by Author "Dalva, Klara"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: A randomized, controlled trial(Humana Press, 2012-09) Baran, Çağdaş; Durdu, Serkan; Dalva, Klara; Zaim, Çağın; Doğan, Arin; Gürman, Günhan; Arslan, Önder; Akar, Ahmet Ruchan; Ocakoğlu, Gökhan; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; AAH-5180-2021; 15832295800We investigated the effects of short-term use of atorvastatin on CD34+/VEGF-R2+/CD133+/CD45- endothelial progenitor cell (EPC) count after on-pump coronary artery bypass surgery (CABG). Between Feb-2010 and May-2010, we randomly assigned, in a placebo-controlled, double-blind study, 60 consecutive patients who underwent isolated, first-time CABG to receive either 14-day atorvastatin (40 mg/day) or placebo preoperatively. Urgent CABG and recent myocardial infarction were excluded. EPCs were quantified (cells/mu l) by flow cytometric phenotyping obtained from venous blood samples collected preoperatively (T-1), 6-hours (T-2), and on the 5th day postoperatively (T-3). Levels of markers of inflammation and serum cardiac troponin I were also measured preoperatively and daily until day-5 after surgery. There were no differences in baseline risk factors including cholesterol profiles, and EuroSCORES between the groups. The composite primary end-point, favored statin group with higher amount of circulating, early EPC count (cells/mu l) at all time points compared with placebo (T-1, 2.30 +/- 0.02 versus 1.58 +/- 0.03, p < 0.001; T-2, 5.00 +/- 0.06 versus 2.19 +/- 0.06, p < 0.001; T-3, 3.03 +/- 0.08 versus 1.78 +/- 0.02, p < 0.001). Postoperative hsCRP rise were inversely correlated with EPC count, and were significantly lower in the statin group (T-1, 0.8 +/- 0.1 versus 2.2 +/- 1.5, p < 0.001; T-2, 72.9 +/- 3.2 versus 96.0 +/- 3.6, p < 0.001; T-3, 4.3 +/- 1.2 versus 11.4 +/- 4.1, p < 0.001). Furthermore, the incidence of postoperative atrial fibrillation was significantly lower in the statin group compared to placebo (3.3% versus 23%, p = 0.02). Short-term atorvastatin use increases circulating early EPCs both pre- and post-operatively and is associated with better preservation of sinus rhythm and reduced hsCRP levels.Item Quantification of mesenchymal stem cells in grafts adds to the benefits of haematopoietic stem cell and T-cell analysis in prediction of the duration of aplasia but not probability of acute graft-versus-host disease: Preliminary results(Springernature, 2009-03) Dalva, Klara; Ayyıldız, Erol; Ersoy, H.; Ertem, Mehmet; İkincioğulları, Aydan; İlhan, O.; Beksaç, Mehmet Sinan; Özçelik, Tülay; Uludağ Üniversitesi/Tıp Fakültesi.Item Screening for hemochromatosis in Turkey(Springer, 2004-03) Bozkaya, Hakan; Bektaş, Mehmet; Metin, Olga; Erkan, Özlem E.; İbrahimoğlu, Dicle; Dalva, Klara; Akbıyık, Filiz; Bozdayı, Abdurrahman Mithat; Akay, Cemal; Yurdaydın, Cihan; Aslan, Önder; Uzunalimoğlu, Özden; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Bilim Dalı.; 7003706434In this study we screened 3060 consecutive blood donors for an unbound iron-binding capacity level of <28 mu M and then performed HFE mutation analysis in these subjects. Sixty-five of the 75 subjects with a low initial unbound iron-binding capacity (all had normal ferritin levels) came back and only 5 (8%) had a low fasting unbound iron-binding capacity. Mutational analysis revealed H63D heterozygosity in two of five subjects. Four of five subjects had liver biopsy indication and none had increased liver iron. HFE genotyping of 60 subjects with a low initial but normal fasting unbound iron-binding capacity revealed heterozygote H63D in seven (11.6%). No allelic variant of position 282 or 63 was found in three previously diagnosed patients with hereditary hemochromatosis. In conclusion, full phenotypic expression of hereditary hemochromatosis is very rare in Turkey. The absence of HFE mutations in three patients with hereditary hemochromatosis suggests that hereditary hemochromatosis in Turkey occurs without common HFE mutations.